Skye Bioscience

SKYE

市值 US$686萬

Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript

Combined company to trade on Nasdaq and operate as Fibrx Therapeutics, a fibrosis-focused company led by the Redx management team and board Company's lead program will be RXC008, Redx's GI-restricted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, with an open U.S. IND, FDA Fast Track designation, and a planned Phase 2 clinical study Concurrent aggregate financings of approximately $125 million committed by a syndicate of new and existing leading healthcare institutional investors Financings expected to fund operations through RXC008 Phase 2 clinical trial – topline data expected H2 2028 Companies to hold a joint conference call on August 14, 2026 at 10 a.m. ET SAN DIEGO and ALDERLEY PARK, United Kingdom, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (“Skye”) (Nasdaq: SKYE), and Redx Pharma Limited (“Redx”), a U.K. based, privately-held clinical-stage biotechnology company focused on developing novel, small molecule, targeted medicines for fibrotic disease, today announced that they have entered into a definitive transaction agreement (the “Transaction Agreement”).

SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that the Cohort Review Committee (CRC) responsible for reviewing safety data generated from the CBeyond Part C Expansion Study, and for approving the opening of enrollment in Cohort 2 has unanimously approved opening the second cohort of the CBeyond Part C Expansion study. The CRC focuses exclusively on the safety of the Part C Expansion Study and does not conduct efficacy assessments.

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2026, along with recent business updates and anticipated milestones.

SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2026, along with recent business updates and anticipated milestones. “Since our March update, execution has focused on turning CBeyond into a Phase 2b-ready development program,” said Punit Dhillon, President & CEO of Skye. “We have now initiated enrollment of Cohort 1 of the CBeyond Expansion Study, executed the compatibility and in-use study with ENHANZE to support a practical high-volume subcutaneous approach, and engaged external development advisors to help pressure-test our target product profile, dose-selection rationale and Phase 2b trial design. Our objective in 2026 remains focused on defining the dose and exposure that can support a larger Phase 2b study evaluating nimacimab as a complementary add-on approach for GLP-1-experienced patients.”

NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Skye Bioscience, Inc. (NASDAQ: SKYE) breached their fiduciary duties to shareholders.

SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present at the GLP-1-Based Therapeutics Summit in Boston, MA, being held April 14-16. Presentation Details Title: Maximizing Efficacy, Minimizing Risk by Leveraging Peripheral CB1 Antagonism in Combination with GLP-1 Agonists to Advance the Obesity Treatment Paradigm Presenter: Punit Dhillon, President & CEO Date: Thursday, April 16, 2026 Time: 1:30 pm About Nimacimab Nimacimab is a potential first-in-class, peripherally-restricted monoclonal antibody inhibitor of the CB1 receptor.

Topline safety and pharmacokinetic data expected in Q4 2026; an independent Data Monitoring Committee is overseeing the study Topline safety and pharmacokinetic data expected in Q4 2026; an independent Data Monitoring Committee is overseeing the study

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025, along with key accomplishments and upcoming milestones.